Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

PPARgamma and GLUT-4 expression as developmental regulators/markers for preadipocyte differentiation into an adipocyte.

Fernyhough ME., Okine E., Hausman G., Vierck JL., Dodson MV.

Narrative Review, published in Domest Anim Endocrinol (2007) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Domest Anim Endocrinol (2007)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
17560753
DOI
10.1016/j.domaniend.2007.05.001

Abstract (original English)

In this document, we have integrated knowledge about two major cellular markers found in cells of the adipocyte lineage (an adipogenic marker and a metabolic marker). This review provides information as to how differentiation of a cell (such as an adipofibroblast, fibroblast or preadipocyte) to become a viable (and new) adipocyte is under different regulation than that experienced by an immature adipocyte that is just beginning to accumulate lipid. The differentiation, prior to lipid-filling, involves PPARgamma. Subsequently, lipid-filling of the adipocyte relies on a late subset of genes and, depending on depot specificity, involves GLUT-4 or any number of other metabolic markers.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AdipocytesAnimalsCCAAT-Enhancer-Binding ProteinsCell DifferentiationCytokinesFatty AcidsGene Expression RegulationGlucose Transporter Type 4HumansHydrocortisone

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.